EndoCare Therapeutics
Develops a non-invasive diagnostic tool for endometriosis that utilizes molecular methods and deep learning-based artificial intelligence to identify biomarkers associated with the disease. This cost-effective solution enables early detection and accurate diagnosis, improving patient outcomes and reducing the financial burden of endometriosis management.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Funding
Founders
Product
Problem
Endometriosis diagnosis currently relies on invasive surgical procedures, leading to delayed diagnosis and treatment, increased healthcare costs, and prolonged patient suffering. The lack of non-invasive diagnostic tools hinders early detection and effective management of the disease.
Solution
EndoCare Therapeutics is developing a non-invasive diagnostic tool for endometriosis that utilizes molecular methods and deep learning-based artificial intelligence to identify biomarkers associated with the disease. By analyzing a comprehensive panel of biomarkers, the solution enables early detection and accurate diagnosis of endometriosis, reducing the need for surgical intervention. The cost-effective diagnostic approach aims to improve patient outcomes, reduce healthcare expenses, and enhance the overall well-being of women affected by endometriosis.
Target Audience
The primary target audience includes healthcare providers, such as gynecologists and primary care physicians, who diagnose and manage women's health, as well as women experiencing symptoms suggestive of endometriosis.
Features
- Non-invasive diagnostic test using molecular methods
- Deep learning-based artificial intelligence for biomarker identification
- Comprehensive panel of biomarkers for accurate endometriosis diagnosis
- Cost-effective solution for reducing healthcare expenses
- Early detection capabilities for improved patient outcomes